Slaughter and May Advises GlaxoSmithKline in Divestment
LawFuel.com – Slaughter and May is advising GlaxoSmithKline plc (GSK) on the divestment to Novartis of its rights in ofatumumab for auto-immune indications, including multiple sclerosis, for up to US$1 billion. Novartis will pay US$300 million on closing, with further payments of up to US$734 million on the achievement of certain milestones and royalties of
Slaughter and May Advises GlaxoSmithKline in Divestment Read More »








